gemfibrozil and bezafibrate

gemfibrozil has been researched along with bezafibrate in 128 studies

Research

Studies (128)

Timeframe	Studies, this research(%)	All Research%
pre-1990	10 (7.81)	18.7374
1990's	49 (38.28)	18.2507
2000's	51 (39.84)	29.6817
2010's	17 (13.28)	24.3611
2020's	1 (0.78)	2.80

Authors

Authors	Studies
Abraham, DJ; Kennedy, PE; Mehanna, AS; Patwa, DC; Williams, FL	1
Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T	1
Abuo-Rahma, Gel-D; Aly, OM; Idrees, GA; Radwan, MF	1
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J	1
Maillet, EL; Margolskee, RF; Mosinger, B	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Fujiwara, R; Koga, T; Nakajima, M; Yokoi, T	1
Fent, K; Popovic, M; Smital, T; Zaja, R	1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL	1
Kashihara, M; Mizuguchi, M; Yokoyama, T	1
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Sánchez, RM	1
Bergmann, S; Fücker, K; Gross, P; Hanefeld, M; Hora, C; Julius, U	1
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Sánchez, R	1
de la Iglesia, FA; Gray, RH; Lucas, JA; McGuire, EJ	1
Alvarez, L; Aránega, A; Aránega, AE; Fernández, JE; González, FJ; Muros, MA; Prados, J; Vélez, C	1
Alvarez, L; Aránega, A; Aránega, AE; Fernández, JE; González, FJ; Linares, A; Muros, MA; Vélez, C	1
Schwandt, P	1
Frishman, WH; Kahn, S; Zimetbaum, P	1
Kłosiewicz-Latoszek, L; Szostak, WB	1
Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G	1
Shapiro, DR; Walker, JF	1
Carlson, LA	1
Arsenio, L; Rossi, A	1
Acacia, E; Jones, C; Kremer, P; Marowski, C	1
Krause, BR; Newton, RS	1
Weisweiler, P	1
Hunninghake, DB; Peters, JR	1
Grundy, SM; Vega, GL	1
Eacho, PI; Foxworthy, PS	1
Hirst, DG; Schwartz, HC; Wood, PJ	1
Maxwell, RE; Nawrocki, JW; Uhlendorf, PD	1
Adzet, T; Alegret, M; Cerqueda, E; Ferrando, R; Laguna, JC; Merlos, M; Sánchez, RM; Vázquez, M	1
Abate, N; Bertolotti, M; Carulli, N; Concari, M; Guicciardi, ME; Loria, P; Pinetti, A	1
Alvarez, L; Aránega, A; Aránega, AE; Gonzalez, AR; Melguizo, C; Muros, MA; Vélez, C	1
Schonfeld, G	1
Dujovne, CA; Lozada, A	1
Adzet, T; Alegret, M; Ferrando, R; Laguna, JC; Merlos, M; Vázquez, M	1
Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J	1
Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D	1
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Sánchez, RM; Vázquez, M; Viñals, M	2
Shepherd, J	1
Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W	1
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM	1
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Muñoz, S; Vázquez, M	1
Adzet, T; Alegret, M; Laguna, JC; López, M; Merlos, M; Rodríguez, C; Vázquez, M	1
Coulter, DM	1
Baldassarre, D; Banfi, C; Mussoni, L; Sironi, L; Tremoli, E	1
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME	1
Adzet, T; Laguna, JC; Merlos, M; Vázquez, M	1
Aranega, A; Aranega, AE; Gonzalez, FJ; Melguizo, C; Prados, JC; Velez, MC	1
Diemer, S; Eberlein-König, B; Przybilla, B	1
Auerbach, BJ; Barnett, BC; Bisgaier, CL; Bousley, R; Essenburg, AD; Kieft, KA; Krause, BR; Newton, RS; Stanfield, R	1
Amacher, DE; Beck, R; Kenny, CV; Schomaker, SJ	1
Grover, S; Hamilton, VH; Lavoie, F; Perreault, S	1
de Wit, EC; Huisman, H; Kaptein, A; Neele, DM; Princen, HM	1
Arrol, S; Bhatnagar, D; Durrington, PN; Julier, K; Mackness, MI; Morgan, J; Prais, H; Wood, GN	1
Sinzinger, H	1
Charach, G; Grosskopf, I; Weintraub, MS	1
Beggs, PW; Clark, DW; Coulter, DM; Williams, SM	1
Bergemann, R; Brandt, A; Siegrist, W	1
Avramopoulos, A; Kounis, N; Kouskoukis, K; Pispirigos, K; Simopoulos, K	1
Wallace, KB; Zhou, S	1
Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T	1
Bellamy, FD; Chaput, E; Edgar, AD; Maubrou-Sanchez, D	1
Bottoni, P; Ficarra, S; Giardina, B; Nocca, G; Puggioni, P; Remiddi, F; Rumi, C; Scatena, R; Sole, PD	1
Jones, PH	1
Brinton, EA; Krakoff, J; Vela, BS	1
Durrington, P	1
Faergeman, O	1
Oboubie, K; Ogunko, A	1
Abramowicz, D; Antoine, M; Broeders, N; Knoop, C; Tielemans, C	1
Black, DM	1
Rubins, HB	1
Barter, PJ; Dimmitt, SB; Watts, GF	1
Backman, JT; Kivistö, KT; Kyrklund, C; Laitila, J; Neuvonen, M; Neuvonen, PJ	1
Hamilton-Craig, I	1
Mikhailidis, DP; Rizos, E	2
Kamaliah, MD; Sanjay, LD	1
Muscari, A; Puddu, GM; Puddu, P	1
Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V	1
Bellido, A; Cabrero, A; Laguna, JC; Novell, F; Rodríguez, C; Roglans, N; Ros, E; Zambón, D	1
Bortolini, M; Farnier, M; Freudenreich, MO; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ	1
Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R	1
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D	1
Boden, WE	1
Dejager, S; Farnier, M; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ	1
Alegret, M; Laguna, JC; Novell, F; Roglans, N; Ros, E; Sánchez, RM; Vázquez-Carrera, M; Zambón, D	1
Agellon, LB; Gbaguidi, GF	1
Dobordzhginidze, LM; Gratsianskiĭ, NA	1
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A	1
Bottoni, P; De Sole, P; Ferrari, F; Giardina, B; Martorana, GE; Rossi, C; Scatena, R	1
Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J	1
Malcolm, J; Meggison, H; Sigal, R	1
Brennan, SO; George, PM; Maghzal, GJ	1
Bartos, J; Dolezel, J; Ehrmann, J; Kolar, Z; Malikova, J; Strakova, N	1
Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ	1
Lee, LE; Liu, G; Metcalfe, CD; Moon, TW; Trudeau, VL	1
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A	1
Elisaf, MS; Mikhailidis, DP; Milionis, HJ	1
Hauzer, A; Komsta, Ł; Majchrzak, E; Misztal, G	1
Duriez, P; Fruchart, JC	1
Patel, J	1
Arnaout, A; Malcolm, J; Sigal, R	1
Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM	1
Isidori, M; Nardelli, A; Parrella, A; Pascarella, L; Rubino, M	1
Berneis, K; Rizzo, M	1
Betti, M; Canesi, L; Ciacci, C; Gallo, G; Lorusso, LC; Marcomini, A; Poiana, G; Regoli, F	1
Gonzalez, FJ; Hossain, MA; Tsujita, M; Yokoyama, S	1
Anzivino, C; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Kienle, MG; Loria, P; Pellegrini, E; Ricchi, M; Zambianchi, L	1
Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S	1
Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL	1
Elsby, R; Holmes, VE; Lambert, C; Sharma, P; Surry, D	1
Bloomgarden, ZT; Drexler, A	1
Boltes, K; García-Calvo, E; Rosal, R	1
Oliveira, HC; Patrício, PR; Raposo, HF; Simões, MC	1
Dijkstra, IM; Kemp, S; Ofman, R; Schackmann, MJ; Wanders, RJ	1
Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D	1
Heo, TH; Hong, M; Jun, HS; Kim, SJ; Lee, HK; Lee, YS; Song, KD; Yi, S	1
González, I; Loera, O; Ramírez-Saad, H; Rodríguez-Nava, O	1
Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S	1
Fang, J; Guo, K; Hou, S; Hua, Z; Kong, X; Li, X; Ren, Z; Wu, Z	1
Chen, YH; Hu, P; Peng, ML; Ren, H; Zhan, Z	1

Reviews

31 review(s) available for gemfibrozil and bezafibrate

Article	Year
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. Journal of clinical pharmacology, 1991, Volume: 31, Issue:1 Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides	1991
Effect of fibric acid derivatives on blood lipid and lipoprotein levels. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids	1987
Fibric acids: effects on lipids and lipoprotein metabolism. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Bile Acids and Salts; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Pentanoic Acids; Triglycerides	1987
The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis, 1994, Volume: 111, Issue:2 Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors	1994
Drug interactions with fibric acids. Pharmacology & therapeutics, 1994, Volume: 63, Issue:2 Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids	1994
Mechanism of action of fibrates. Postgraduate medical journal, 1993, Volume: 69 Suppl 1 Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL	1993
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6 Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male	1997
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis]. Deutsche medizinische Wochenschrift (1946), 1998, Sep-18, Volume: 123, Issue:38 Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis	1998
Fibrates and high-dose statins to prevent coronary heart disease events. Current cardiology reports, 1999, Volume: 1, Issue:3 Topics: Angioplasty, Balloon, Coronary; Bezafibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Myocardial Revascularization; Randomized Controlled Trials as Topic; Triglycerides	1999
The role of fibric acid derivatives in the secondary prevention of coronary heart disease. Current cardiology reports, 2000, Volume: 2, Issue:5 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides	2000
Hypertriglyceridemia and the fibrate trials. Current opinion in lipidology, 2000, Volume: 11, Issue:6 Topics: Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Male; Risk; Triglycerides	2000
Statins in children: what do we know and what do we need to do? Current atherosclerosis reports, 2001, Volume: 3, Issue:1 Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin	2001
Triglycerides and coronary heart disease: implications of recent clinical trials. Journal of cardiovascular risk, 2000, Volume: 7, Issue:5 Topics: Aged; Bezafibrate; Controlled Clinical Trials as Topic; Coronary Artery Disease; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Prognosis; Treatment Outcome; Triglycerides	2000
Normocholesterolaemic dyslipidaemia: is there a role for fibrates? The Medical journal of Australia, 2001, Jan-15, Volume: 174, Issue:2 Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents	2001
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovascular research, 2001, Volume: 52, Issue:2 Topics: Adult; Bezafibrate; Biomarkers; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Triglycerides	2001
Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. International journal of cardiology, 2002, Volume: 82, Issue:3 Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Triglycerides	2002
Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology, 2002, Volume: 97, Issue:3 Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Cholesterol, LDL; Cytochrome P-450 Enzyme System; Digestive System; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver; Renal Insufficiency; Rhabdomyolysis; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases	2002
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Current opinion in cardiology, 2003, Volume: 18, Issue:4 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic	2003
Role of fibrates in reducing coronary risk: a UK Consensus. Current medical research and opinion, 2004, Volume: 20, Issue:2 Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome	2004
[Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate]. Kardiologiia, 2004, Volume: 44, Issue:2 Topics: Bezafibrate; Clofibrate; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Male; Randomized Controlled Trials as Topic	2004
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:5 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment	2004
Prevention of cardiovascular events in diabetes. Clinical evidence, 2004, Issue:11 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Coronary Artery Bypass; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation	2004
Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Current medical research and opinion, 2000, Volume: 16, Issue:1 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Myocardial Ischemia; Randomized Controlled Trials as Topic; Triglycerides	2000
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:1 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Fenofibrate; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides	2006
Dyslipidaemia in diabetes. Clinical evidence, 2006, Issue:15 Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2006
Prevention of cardiovascular events in diabetes. Clinical evidence, 2006, Issue:15 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopidogrel; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation; Ticlopidine	2006
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. Journal of the National Cancer Institute, 2006, Nov-01, Volume: 98, Issue:21 Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States	2006
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Current medical research and opinion, 2007, Volume: 23, Issue:5 Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome	2007
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. The American journal of medicine, 2009, Volume: 122, Issue:10 Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome	2009
Fibrates for secondary prevention of cardiovascular disease and stroke. The Cochrane database of systematic reviews, 2015, Oct-25, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke	2015
Fibrates for primary prevention of cardiovascular disease events. The Cochrane database of systematic reviews, 2016, 11-16, Volume: 11 Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke	2016

Trials

13 trial(s) available for gemfibrozil and bezafibrate

Article	Year
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. Fortschritte der Medizin, 1992, Dec-20, Volume: 110, Issue:35-36 Topics: Adult; Aged; Bezafibrate; Cholesterol; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipoproteins; Male; Middle Aged; Triglycerides	1992
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis, 1990, Volume: 85, Issue:2-3 Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin	1990
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia. The American journal of cardiology, 1990, Mar-20, Volume: 65, Issue:12 Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin	1990
Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb. Current medical research and opinion, 1989, Volume: 11, Issue:5 Topics: Adult; Aged; Argentina; Arteriosclerosis; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Triglycerides	1989
Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia. Arzneimittel-Forschung, 1988, Volume: 38, Issue:7 Topics: Adult; Aged; Bezafibrate; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged	1988
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clinical cardiology, 1995, Volume: 18, Issue:11 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides	1995
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6 Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male	1997
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, Volume: 138, Issue:1 Topics: Adult; Aged; Aryldialkylphosphatase; Bezafibrate; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Double-Blind Method; Esterases; Female; Fibrinogen; Gemfibrozil; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Plasminogen Activators	1998
Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis, 1998, Volume: 141 Suppl 1 Topics: Bezafibrate; Chylomicrons; Gemfibrozil; Glucose Tolerance Test; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, HDL; Male; Metformin; Middle Aged; Postprandial Period	1998
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clinical pharmacology and therapeutics, 2001, Volume: 69, Issue:5 Topics: Adult; Area Under Curve; Bezafibrate; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male	2001
Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:6 Topics: Acyl-CoA Oxidase; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Carnitine O-Palmitoyltransferase; Cholecystectomy; Cholelithiasis; Cholesterol, HDL; Cholesterol, LDL; DNA Primers; Female; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Liver; Male; Middle Aged; Oxidoreductases; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Stearoyl-CoA Desaturase; Transcription Factors; Triglycerides	2002
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9, Issue:3 Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1	2003
Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. European journal of clinical pharmacology, 2004, Volume: 59, Issue:12 Topics: Bezafibrate; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Down-Regulation; Female; Fenofibrate; Gallstones; Gemfibrozil; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction	2004

Other Studies

85 other study(ies) available for gemfibrozil and bezafibrate

Article	Year
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids. Journal of medicinal chemistry, 1984, Volume: 27, Issue:8 Topics: Acetates; Animals; Antisickling Agents; Benzyl Compounds; Binding Sites; Glycolates; Humans; Mice; Models, Molecular; Oxygen; Phenoxyacetates; Structure-Activity Relationship; X-Ray Diffraction	1984
Characterization of the drug binding specificity of rat liver fatty acid binding protein. Journal of medicinal chemistry, 2008, Jul-10, Volume: 51, Issue:13 Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity	2008
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives. European journal of medicinal chemistry, 2009, Volume: 44, Issue:6 Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypolipidemic Agents; Male; Molecular Structure; Propionates; Rats; Rats, Wistar; Stereoisomerism; Triglycerides	2009
Probing the fibrate binding specificity of rat liver fatty acid binding protein. Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17 Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics	2009
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3. Journal of medicinal chemistry, 2009, Nov-12, Volume: 52, Issue:21 Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Benzene Derivatives; Bezafibrate; Cell Line; Cercopithecidae; Clofibric Acid; Gemfibrozil; Herbicides; Humans; Hypolipidemic Agents; Indoleacetic Acids; Mice; Protein Subunits; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Structure-Activity Relationship	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Comet Assay; DNA Damage; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Hepatocytes; Humans; Kidney	2011
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide. The Journal of biological chemistry, 2013, Nov-22, Volume: 288, Issue:47 Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins	2013
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. PloS one, 2016, Volume: 11, Issue:10 Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat	2016
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. Journal of medicinal chemistry, 2021, 10-14, Volume: 64, Issue:19 Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning; Humans; Prealbumin; Thermodynamics; Triclabendazole	2021
Differential inhibition of long-chain acyl-CoA hydrolases by hypolipidemic drugs in vitro. Biochemical pharmacology, 1992, Feb-04, Volume: 43, Issue:3 Topics: Animals; Bezafibrate; Clofibric Acid; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Palmitoyl Coenzyme A; Palmitoyl-CoA Hydrolase; Rats; Rats, Inbred Strains; Subcellular Fractions	1992
In vitro effect of clofibric acid derivatives on rat hepatic microsomal electron transport chains. Biochemical pharmacology, 1991, Oct-24, Volume: 42, Issue:10 Topics: Animals; Bezafibrate; Clofibric Acid; Cytochromes b5; Electron Transport; Gemfibrozil; Kinetics; Male; Microsomes, Liver; NADH Dehydrogenase; NADPH Dehydrogenase; Rats; Rats, Inbred Strains	1991
Peroxisome induction potential and lipid-regulating activity in rats. Quantitative microscopy and chemical structure-activity relationships. The American journal of pathology, 1991, Volume: 139, Issue:1 Topics: Amides; Animals; Bezafibrate; Gemfibrozil; Lipids; Lipoproteins; Liver; Microbodies; Organ Size; Propionates; Rats; Structure-Activity Relationship	1991
Effects of fibric acid derivatives on accumulation of actin in myocardiocytes. International journal of cardiology, 1991, Volume: 33, Issue:1 Topics: Actins; Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Immunoblotting; Myocardium	1991
Influence of fibric acid derivatives on intermediate filament proteins in myocardiocyte cultures. Life sciences, 1991, Volume: 48, Issue:11 Topics: Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeletal Proteins; Desmin; Fenofibrate; Gemfibrozil; Heart; In Vitro Techniques; Intermediate Filament Proteins; Myocardium; Vimentin	1991
Fibrates and triglyceride metabolism. European journal of clinical pharmacology, 1991, Volume: 40 Suppl 1 Topics: Bezafibrate; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides	1991
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. European journal of clinical pharmacology, 1991, Volume: 40, Issue:1 Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol	1991
[A case of familial hypercholesterolemia with therapeutic difficulties]. Lakartidningen, 1990, Mar-07, Volume: 87, Issue:10 Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin	1990
[Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives]. La Clinica terapeutica, 1989, Dec-31, Volume: 131, Issue:6 Topics: Adult; Bezafibrate; Drug Evaluation; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Propionates; Time Factors	1989
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats. Atherosclerosis, 1986, Volume: 59, Issue:1 Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates	1986
Conditions influencing the induction of peroxisomal beta-oxidation in cultured rat hepatocytes. Toxicology letters, 1986, Volume: 30, Issue:2 Topics: Animals; Bezafibrate; Catalase; Cell Survival; Clofibric Acid; Fibric Acids; Gemfibrozil; In Vitro Techniques; Liver; Male; Microbodies; Pentanoic Acids; Rats; Rats, Inbred F344	1986
The modification of hemoglobin affinity for oxygen and tumor radiosensitivity by antilipidemic drugs. Radiation research, 1987, Volume: 112, Issue:1 Topics: Animals; Bezafibrate; Clofibrate; Combined Modality Therapy; Gemfibrozil; Hemoglobins; Hypolipidemic Agents; Mice; Neoplasm Transplantation; Oxygen; Pentanoic Acids; Radiation-Sensitizing Agents; Sarcoma, Experimental	1987
Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats. Atherosclerosis, 1983, Volume: 48, Issue:3 Topics: Animals; Anticholesteremic Agents; Bezafibrate; Caprylates; Carbon Radioisotopes; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Lovastatin; Male; Mevalonic Acid; Naphthalenes; Pentanoic Acids; Rats; Rats, Inbred F344; Sterols; Valerates	1983
Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation. British journal of pharmacology, 1995, Volume: 114, Issue:7 Topics: Acetyltransferases; Animals; Bezafibrate; Clofibrate; Dietary Fats; Fatty Acid Desaturases; Fatty Acid Elongases; Fatty Acids; Gemfibrozil; Male; Microbodies; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Time Factors	1995
Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans. Arteriosclerosis, thrombosis, and vascular biology, 1995, Volume: 15, Issue:8 Topics: Adult; Bezafibrate; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged	1995
Changes in subcellular accumulation of contractile proteins in myocardiocyte cultures: effects of fibric acid derivatives. Journal of cardiovascular pharmacology, 1993, Volume: 21, Issue:1 Topics: Actinin; Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Contractile Proteins; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Immunoblotting; Myocardial Contraction; Myocardium; Tropomyosin; Troponin; Troponin T	1993
Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. British journal of pharmacology, 1994, Volume: 112, Issue:2 Topics: Animals; Bezafibrate; Cholesterol; Clofibrate; Coenzyme A Ligases; Diet; Gemfibrozil; Hypolipidemic Agents; Lipids; Liver; Male; Microbodies; Organ Size; Palmitoyl-CoA Hydrolase; Rats; Rats, Sprague-Dawley; Repressor Proteins; Saccharomyces cerevisiae Proteins; Triglycerides	1994
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis. Cardiovascular research, 1994, Volume: 28, Issue:5 Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein	1994
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin	1993
Fibrates modify rat hepatic fatty acid chain elongation and desaturation in vitro. Biochemical pharmacology, 1993, Nov-17, Volume: 46, Issue:10 Topics: Acetyltransferases; Animals; Bezafibrate; Clofibric Acid; Cytosol; Fatty Acid Desaturases; Fatty Acid Elongases; Gemfibrozil; Liver; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley	1993
Cytosolic lipogenic enzymes: effect of fibric acid derivatives in vitro. Life sciences, 1993, Volume: 52, Issue:2 Topics: Animals; Bezafibrate; Clofibric Acid; Cytosol; Enzyme Inhibitors; Fatty Acids; Gemfibrozil; Kinetics; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley	1993
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. The Biochemical journal, 1996, Mar-15, Volume: 314 ( Pt 3) Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S	1996
Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. British journal of pharmacology, 1995, Volume: 116, Issue:3 Topics: Animals; Bezafibrate; Cell Division; Clofibrate; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Gemfibrozil; Hypolipidemic Agents; Lipids; Liver; Male; Microbodies; Phosphatidylcholines; Phosphatidylethanolamines; Rats; Rats, Sprague-Dawley; Time Factors	1995
Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs. British journal of pharmacology, 1995, Volume: 116, Issue:8 Topics: Animals; Bezafibrate; Clofibrate; Fatty Acid Synthases; Fatty Acids; Gemfibrozil; Guinea Pigs; Hypolipidemic Agents; Male; Microsomes, Liver; NADH Dehydrogenase; NADPH-Ferrihemoprotein Reductase; Palmitoyl-CoA Hydrolase; Phospholipids	1995
Reasons for stopping drugs are monitored in New Zealand. BMJ (Clinical research ed.), 1996, Sep-21, Volume: 313, Issue:7059 Topics: Adverse Drug Reaction Reporting Systems; Bezafibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; New Zealand; Product Surveillance, Postmarketing; Simvastatin	1996
Plasminogen activator inhibitor type 1 secretion by HepG2 cells: opposite effects of two fibric acid derivatives. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1996, Volume: 7, Issue:4 Topics: Bezafibrate; Cell Line; Gemfibrozil; Humans; Plasminogen Activator Inhibitor 1	1996
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. Journal of lipid research, 1995, Volume: 36, Issue:12 Topics: Animals; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides	1995
Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. British journal of pharmacology, 1996, Volume: 117, Issue:6 Topics: Animals; Antioxidants; Bezafibrate; Clofibrate; Copper Sulfate; Fatty Acids; Gemfibrozil; Hypolipidemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Rats; Rats, Sprague-Dawley	1996
Modulation of cardiac intermediate filament proteins in the chick heart by fibric acid derivatives. European journal of morphology, 1995, Volume: 33, Issue:5 Topics: Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeleton; Densitometry; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Intermediate Filament Proteins; Myocardium	1995
Evaluation of the phototoxic properties of some hypolipidemics in vitro: fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region. Journal of dermatological science, 1996, Volume: 13, Issue:2 Topics: Bezafibrate; Clofibrate; Dermatitis, Phototoxic; Drug Evaluation, Preclinical; Fenofibrate; Gemfibrozil; Hemolysis; Humans; Hypolipidemic Agents; In Vitro Techniques; Ultraviolet Rays	1996
Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats. Atherosclerosis, 1996, Nov-15, Volume: 127, Issue:1 Topics: Animals; Apolipoproteins B; Apolipoproteins E; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Gemfibrozil; Hypertriglyceridemia; Hypolipidemic Agents; Immunoelectrophoresis; Lipoprotein Lipase; Liver; Male; Rats; Rats, Sprague-Dawley; Spectrophotometry; Triglycerides	1996
Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. Toxicology and applied pharmacology, 1997, Volume: 142, Issue:1 Topics: Animals; Anticholesteremic Agents; Bezafibrate; Clofibrate; Cyclin-Dependent Kinases; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Female; Gemfibrozil; Isoenzymes; Liver; Male; Microbodies; Microsomes, Liver; Mixed Function Oxygenases; Organ Size; Oxidation-Reduction; Palmitoyl Coenzyme A; Proliferating Cell Nuclear Antigen; Rats; Rats, Inbred Strains; Sex Characteristics	1997
No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased. Biochemical and biophysical research communications, 1998, Mar-17, Volume: 244, Issue:2 Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Bezafibrate; Cells, Cultured; Clofibrate; Clofibric Acid; Gemfibrozil; Humans; Liver; Macaca fascicularis	1998
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). British journal of clinical pharmacology, 1999, Volume: 47, Issue:1 Topics: Bezafibrate; Cohort Studies; Comorbidity; Diabetes Complications; Female; Gemfibrozil; Humans; Hypertension; Lipids; Male; Myocardial Ischemia; New Zealand; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Random Allocation; Retrospective Studies; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome	1999
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson). PharmacoEconomics, 1993, Volume: 3, Issue:2 Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome	1993
Evaluation of kidney and liver subacute toxicity induced by Bezalip-Pravastatin-Lopid antihyperlipidaemic compounds in rats. Biochemistry and molecular biology international, 1999, Volume: 47, Issue:3 Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antihypertensive Agents; Aspartate Aminotransferases; Bezafibrate; Enzyme Inhibitors; gamma-Glutamyltransferase; Gemfibrozil; Hydroxymethylglutaryl CoA Reductases; Kidney; Liver; Male; Pravastatin; Rats; Rats, Wistar	1999
The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicological sciences : an official journal of the Society of Toxicology, 1999, Volume: 48, Issue:1 Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene	1999
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:6 Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic	1999
Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol. Lipids, 1999, Volume: 34, Issue:5 Topics: Animals; Bezafibrate; Drug Synergism; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Rats; Rats, Sprague-Dawley; Vitamin E	1999
Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell death and differentiation, 1999, Volume: 6, Issue:8 Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Bezafibrate; Biomarkers; Cell Cycle; Cell Differentiation; Clofibric Acid; Gemfibrozil; Growth Inhibitors; HL-60 Cells; Humans; Integrin alphaXbeta2; K562 Cells; Leukemia, Myeloid; Lipopolysaccharide Receptors; U937 Cells	1999
A case for lipid-lowering? Diabetic medicine : a journal of the British Diabetic Association, 2000, Volume: 17 Suppl 2 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides	2000
Therapy and clinical trials. Current opinion in lipidology, 2000, Volume: 11, Issue:6 Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hypolipidemic Agents	2000
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:12 Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplantation; Postoperative Period; Retrospective Studies; Urea	2000
Normocholesterolaemic dysslipidaemia: is there a role for fibrates? The Medical journal of Australia, 2001, Jun-04, Volume: 174, Issue:11 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Pyridines; Treatment Outcome; Triglycerides	2001
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. Prescrire international, 1999, Volume: 8, Issue:42 Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome	1999
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore medical journal, 2001, Volume: 42, Issue:8 Topics: Acute Kidney Injury; Aged; Bezafibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases; Male; Rhabdomyolysis	2001
Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis, 2002, Volume: 165, Issue:1 Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome	2002
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). The American journal of cardiology, 2003, Jan-15, Volume: 91, Issue:2 Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged	2003
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn-Schmiedeberg's archives of pharmacology, 2003, Volume: 367, Issue:3 Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured	2003
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). The American journal of cardiology, 2003, Oct-01, Volume: 92, Issue:7 Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Retrospective Studies; Sex Factors; Treatment Outcome; Triglycerides	2003
The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer. Nucleic acids research, 2004, Volume: 32, Issue:3 Topics: Acids, Acyclic; Animals; Bezafibrate; Binding Sites; Cell Line, Tumor; Cells, Cultured; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Dimerization; DNA-Binding Proteins; Gemfibrozil; Gene Expression Regulation; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Humans; Hydroxycholesterols; Ligands; Liver X Receptors; Nuclear Proteins; Orphan Nuclear Receptors; Promoter Regions, Genetic; Pyrimidines; Rats; Receptors, Cytoplasmic and Nuclear; Repetitive Sequences, Nucleic Acid; Response Elements; Transcription Factors	2004
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. Regulatory peptides, 2004, Aug-15, Volume: 120, Issue:1-3 Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2004
Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochemical and biophysical research communications, 2004, Jul-02, Volume: 319, Issue:3 Topics: Bezafibrate; Cell Differentiation; Cell Division; Clofibric Acid; Dose-Response Relationship, Drug; Electron Transport; Gemfibrozil; HL-60 Cells; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Mitochondria; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones; Transcription Factors	2004
The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy. Thrombosis research, 2005, Volume: 115, Issue:4 Topics: Bezafibrate; Case-Control Studies; Female; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; N-Acetylneuraminic Acid; Pregnancy; Protein Subunits; Spectrometry, Mass, Electrospray Ionization; Thrombin Time	2005
Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma, 2005, Volume: 52, Issue:2 Topics: Apoptosis; Bezafibrate; Brain Neoplasms; Cell Cycle; Cell Differentiation; Cell Survival; Flow Cytometry; Gemfibrozil; Glioblastoma; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; PPAR alpha; PPAR gamma; Thiazolidinediones; Tumor Cells, Cultured	2005
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic & clinical pharmacology & toxicology, 2005, Volume: 97, Issue:4 Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin	2005
A teleost in vitro reporter gene assay to screen for agonists of the peroxisome proliferator-activated receptors. Environmental toxicology and chemistry, 2005, Volume: 24, Issue:9 Topics: Acetyl-CoA C-Acyltransferase; Alitretinoin; Angiogenesis Inhibitors; Animals; Bezafibrate; Cloning, Molecular; DNA; DNA, Complementary; Dose-Response Relationship, Drug; Environmental Monitoring; Gemfibrozil; Genes, Reporter; Humans; Hypolipidemic Agents; In Vitro Techniques; Liver; Luciferases; Oncorhynchus mykiss; Peroxisome Proliferator-Activated Receptors; Peroxisome Proliferators; Plasmids; PPAR alpha; PPAR-beta; Promoter Regions, Genetic; Pyrimidines; Rats; Retinoid X Receptors; Transcription, Genetic; Transfection; Tretinoin; Water Pollutants, Chemical	2005
Differential associations of statin and fibrate treatment with carotid arterial remodeling. American journal of hypertension, 2005, Volume: 18, Issue:11 Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography	2005
Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals. Journal of pharmaceutical and biomedical analysis, 2006, May-03, Volume: 41, Issue:2 Topics: Bezafibrate; Buffers; Clofibric Acid; Electrophoresis, Capillary; Fibric Acids; Gemfibrozil; Hydrogen-Ion Concentration; Hypolipidemic Agents; Pharmaceutical Preparations; Reproducibility of Results; Temperature; Time Factors	2006
Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms. Environment international, 2007, Volume: 33, Issue:5 Topics: Aliivibrio fischeri; Animals; Bezafibrate; Chlorophyta; Crustacea; Escherichia coli; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Lethal Dose 50; Mutagenicity Tests; No-Observed-Adverse-Effect Level; Rotifera; Salmonella typhimurium; Toxicity Tests, Acute; Toxicity Tests, Chronic; Ultraviolet Rays; Water Pollutants, Chemical	2007
Effects of blood lipid lowering pharmaceuticals (bezafibrate and gemfibrozil) on immune and digestive gland functions of the bivalve mollusc, Mytilus galloprovincialis. Chemosphere, 2007, Volume: 69, Issue:6 Topics: Animals; Bezafibrate; Cell Membrane; Digestive System; Dose-Response Relationship, Drug; Gemfibrozil; Hemocytes; Hypolipidemic Agents; Lipids; Mytilus; Phagocytosis; Water Pollutants, Chemical	2007
Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:3 Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blotting, Western; Cells, Cultured; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Hepatocytes; Hypolipidemic Agents; Lipoproteins, HDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Propionates; Triazoles	2008
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids, 2008, Volume: 73, Issue:11 Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Complement C4; Data Interpretation, Statistical; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Reference Standards; Simvastatin	2008
On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis, 2009, Volume: 205, Issue:2 Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles	2009
Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica; the fate of foreign compounds in biological systems, 2010, Volume: 40, Issue:1 Topics: Antirheumatic Agents; Bezafibrate; Biological Transport; Cell Line; Drug Interactions; Estradiol; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Rifamycins	2010
Fibrate use in diabetes: new concepts. Journal of diabetes, 2011, Volume: 3, Issue:1 Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents	2011
Toxicity of mixtures of perfluorooctane sulphonic acid with chlorinated chemicals and lipid regulators. Chemosphere, 2012, Volume: 86, Issue:1 Topics: Alkanesulfonic Acids; Anti-Infective Agents, Local; Bezafibrate; Chlorophenols; Chlorophyta; Complex Mixtures; Drug Synergism; Fluorocarbons; Gemfibrozil; Hypolipidemic Agents; Lethal Dose 50; Mutagens; Surface-Active Agents; Triclosan; Water Pollutants, Chemical	2012
Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene. The Journal of nutritional biochemistry, 2014, Volume: 25, Issue:6 Topics: Animals; Bezafibrate; Cholesterol Ester Transfer Proteins; Combined Modality Therapy; Corn Oil; Crosses, Genetic; Dietary Supplements; Female; Fenofibrate; Fibric Acids; Fish Oils; Gemfibrozil; Hypertriglyceridemia; Hypolipidemic Agents; Liver; Male; Mice, Transgenic; Random Allocation; RNA, Messenger; Up-Regulation	2014
Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis. Biochimica et biophysica acta, 2015, Volume: 1851, Issue:2 Topics: Acetyltransferases; Adrenoleukodystrophy; Bezafibrate; Enzyme Inhibitors; Fatty Acid Elongases; Fatty Acids; Fibroblasts; Gemfibrozil; HEK293 Cells; Humans; Hypolipidemic Agents; Kinetics; Microsomes; Transfection	2015
Fibrates inhibit the apoptosis of Batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential. In vitro cellular & developmental biology. Animal, 2016, Volume: 52, Issue:3 Topics: Apoptosis; Autophagy; Bezafibrate; Cells, Cultured; Fenofibrate; Gemfibrozil; Humans; Lymphocytes; Membrane Glycoproteins; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Neuronal Ceroid-Lipofuscinoses; Neuroprotective Agents; Oxidative Stress; PPAR alpha	2016
Evaluation of the simultaneous removal of recalcitrant drugs (bezafibrate, gemfibrozil, indomethacin and sulfamethoxazole) and biodegradable organic matter from synthetic wastewater by electro-oxidation coupled with a biological system. Environmental technology, 2016, Volume: 37, Issue:23 Topics: Bezafibrate; Bioreactors; Boron; Diamond; Electrodes; Electrolysis; Gemfibrozil; Indomethacin; Oxidation-Reduction; Sulfamethoxazole; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical	2016
Degradation of lipid regulators by the UV/chlorine process: Radical mechanisms, chlorine oxide radical (ClO Water research, 2018, 06-15, Volume: 137 Topics: Ammonia; Bezafibrate; Chlorine; Chlorine Compounds; Clofibric Acid; Disinfection; Gemfibrozil; Halogenation; Hydroxyl Radical; Hypolipidemic Agents; Kinetics; Oxidation-Reduction; Photolysis; Ultraviolet Rays; Vibrio; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Purification	2018
[A new attempt with lipoprotein lipase agonists in the treatment of nonalcoholic steatohepatitis]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, Jul-20, Volume: 27, Issue:7 Topics: Bezafibrate; Biopsy; Carboxylic Acids; Case-Control Studies; Computational Biology; Enzyme Activators; Gemfibrozil; Glycyrrhizic Acid; Humans; Lipid Metabolism; Lipoprotein Lipase; Non-alcoholic Fatty Liver Disease; Oligonucleotide Array Sequence Analysis; Scavenger Receptors, Class E	2019